March 8, 2021
March 8, 2021 – Genentech has voluntarily withdrawn an indication for Tecentriq® (atezolizumab) to treat
metastatic urothelial carcinoma (mUC) in patients who have previously received
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
March 8, 2021
March 8, 2021 – The U.S. FDA has granted tentative approval for a generic version of AstraZeneca’s Symbicort® (budesonide/formoterol fumarate dihydrate) inhalation aerosol. The generic
March 5, 2021
March 5, 2021 – The U.S. FDA has approved an expanded indication for Flucelvax® Quadrivalent (influenza
vaccine), manufactured by Seqirus. The vaccine is indicated to provide active immunization
March 5, 2021
March 5, 2021 – The U.S. FDA has approved a new indication for Yescarta® (axicabtagene ciloleucel),
manufactured by Gilead, to treat relapsed or refractory follicular lymphoma (FL)
March 4, 2021
March 4, 2021 – The U.S. FDA has approved a new indication for Actemra® (tocilizumab), manufactured
by Roche, to slow the rate of pulmonary function decline in adults who have systemic
March 3, 2021
March 3, 2021 - Important Updates Regarding Additional Populations Eligible to Receive COVID-19 Vaccines and Authorization for Johnson & Johnson's Janssen Biotech, Inc. COVID-19 Vaccine
March 3, 2021
March 3, 2021 – The U.S. FDA has approved AzstarysTM (serdexmethylphenidate/dexmethylphenidate), manufactured by Corium, to treat attention deficit hyperactivity disorder (ADHD) in
March 3, 2021
March 3, 2021 – The U.S. FDA has granted Pfizer’s Lorbrena® (lorlatinib) full approval after first issuing an
accelerated approval in 2018. The agency has also expanded Lorbrena’s approved